Chandler v. Janssen Pharms. Inc., et al.


Patterson Belknap Webb & Tyler LLP successully advised Janssen Pharms on the Risperdal Gynecomastia Case

On a motion for summary judgment, our lawyers successfully argued that the plaintiff had not produced admissible evidence that the drug’s warning was inadequate. A U.S. District Court for the Eastern District of New York judge granted summary judgment on July 6, 2018, finding that the warnings were adequate as a matter of law at all relevant times.

Patterson Belknap Webb & Tyler LLP advised Janssen Pharms. Inc. with a team including John Winter (Picture) and Rachel Schwartz.

Involved fees earner: Rachel Schwartz – Patterson Belknap; John Winter – Patterson Belknap;

Law Firms: Patterson Belknap;

Clients: Janssen Pharmaceuticals, Inc.;

Author: Ambrogio Visconti